Tirzepatide Versus Semaglutide in Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes: A Target Trial Emulation Study
Diabetes,Obesity,and CardioMetabolic CARE · 29.10.2026
DOI: 10.2337/doc26-0074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes,Obesity,and CardioMetabolic CARE, online erschienen am 29.10.2026. Verfasst von John W. Ostrominski und 10 weiteren Autor:innen. Gefördert von: National Institute of Diabetes and Digestive and Kidney Diseases.
Themen: Diabetes mellitus, Herzinsuffizienz
Abstract (Originalsprache)
OBJECTIVE To evaluate the comparative effectiveness of semaglutide and tirzepatide in individuals with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS This target trial emulation study included adults with HFpEF and T2D who were initiating once-weekly tirzepatide or semaglutide (June 2022 to June 2025). The data were from two U.S.-based commercial claims databases. The coprimary outcomes were heart failure (HF) hospitalization and all-cause mortality. Between-group characteristics were balanced through propensity score–based fine stratification. Adjusted incidence rates (IRs) per 1,000 person-years and hazard ratios (HRs) were estimated. RESULTS After fine stratification weighting, the final cohort consisted of 37,183 patients (age, mean ± SD, 67 ± 10 years; 54% women) with HFpEF and T2D newly initiating either tirzepatide (n = 11,780) or semaglutide (n = 25,387). Over a median follow-up of 5.1 months, tirzepatide initiators experienced a lower rate of HF hospitalization when compared with semaglutide initiators (IR 19.7 vs. 25.5, respectively; HR 0.80 [95% CI 0.66–0.96]). No evidence of heterogeneity was observed across key subgroups defined by age, sex, BMI, and baseline use of medications for HF or other cardiovascular conditions. Rates of all-cause mortality between the exposure groups were similar (IR 20.5 vs. 19.5, respectively; HR 0.99 [95% CI 0.81–1.21]). Sensitivity analyses mimicking on-treatment and intention-to-treat approaches revealed similar findings for both coprimary outcomes. CONCLUSIONS Tirzepatide was associated with a lower rate of HF hospitalization but not all-cause mortality when compared with semaglutide in adults with HFpEF and T2D in routine care. These findings may inform treatment selection for individuals with HFpEF and T2D.
Förderung
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Ostrominski, J. W., Ortega-Montiel, J., Alkabbani, W., Cho, H., Everett, B. M., Wexler, D. J., Byrne, C. F., Cromer, S. J., Glynn, R. J., Paik, J. M., & Patorno, E. (2026). Tirzepatide Versus Semaglutide in Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes: A Target Trial Emulation Study. Diabetes,Obesity,and CardioMetabolic CARE. https://doi.org/10.2337/doc26-0074
Vancouver
Ostrominski JW, Ortega-Montiel J, Alkabbani W, Cho H, Everett BM, Wexler DJ, et al. Tirzepatide Versus Semaglutide in Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes: A Target Trial Emulation Study. Diabetes,Obesity,and CardioMetabolic CARE. 2026. doi:10.2337/doc26-0074
BibTeX
@article{Ostrominski2026,
author = {Ostrominski, John W. and Ortega-Montiel, Janinne and Alkabbani, Wajd and Cho, Hanseul and Everett, Brendan M. and Wexler, Deborah J. and Byrne, Caroline F. and Cromer, Sara J. and Glynn, Robert J. and Paik, Julie M. and Patorno, Elisabetta},
title = {Tirzepatide Versus Semaglutide in Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes: A Target Trial Emulation Study},
journal = {Diabetes,Obesity,and CardioMetabolic CARE},
year = {2026},
doi = {10.2337/doc26-0074}
}
EUVIMED